Barclays
CSTL icon

Barclays’s Castle Biosciences CSTL Stock Holding History

Barclays’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$658K Sell
26,810
-45,339
-63% -$1.48M ﹤0.01% 3014
2025
Q4 		$2.81M Sell
72,149
-919
-1% -$29.6K ﹤0.01% 2679
2025
Q3 		$1.66M Sell
73,068
-36,675
-33% -$745K ﹤0.01% 3008
2025
Q2 		$2.24M Buy
109,743
+66,928
+156% +$1.24M ﹤0.01% 2756
2025
Q1 		$857K Sell
42,815
-6,198
-13% -$153K ﹤0.01% 3198
2024
Q4 		$1.31M Sell
49,013
-3,288
-6% -$100K ﹤0.01% 3195
2024
Q3 		$1.49M Buy
52,301
+39,567
+311% +$1.01M ﹤0.01% 3085
2024
Q2 		$277K Sell
12,734
-34,691
-73% -$773K ﹤0.01% 3390
2024
Q1 		$1.05M Buy
47,425
+8,045
+20% +$175K ﹤0.01% 3081
2023
Q4 		$850K Buy
39,380
+30,398
+338% +$535K ﹤0.01% 3562
2023
Q3 		$152K Sell
8,982
-528
-6% -$9.23K ﹤0.01% 3414
2023
Q2 		$130K Sell
9,510
-2,944
-24% -$59.7K ﹤0.01% 3454
2023
Q1 		$283K Buy
12,454
+5,866
+89% +$143K ﹤0.01% 3609
2022
Q4 		$155K Sell
6,588
-18,646
-74% -$432K ﹤0.01% 3985
2022
Q3 		$658K Buy
25,234
+24,040
+2,013% +$674K ﹤0.01% 2517
2022
Q2 		$26K Sell
1,194
-2,359
-66% -$54.8K ﹤0.01% 4291
2022
Q1 		$159K Buy
+3,553
New +$147K ﹤0.01% 3556

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's CSTL Position: Q1 2026 in Review

Barclays reduced its Castle Biosciences (CSTL) stake by 63% in Q1 2026, selling an estimated $1.48M and leaving 26,810 shares worth $658K. The position accounts for ﹤0.01% of the portfolio, ranked #3014.

Barclays first reported a position in CSTL in Q1 2022 and has held it in 17 quarters since. The position peaked at $2.81M in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Barclays held 26,810 shares of Castle Biosciences worth $658K as of Q1 2026.
  • Barclays sold 45,339 Castle Biosciences shares in Q1 2026, an estimated $1.48M.
  • Castle Biosciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3014 holding.
  • Barclays first reported a position in Castle Biosciences in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Castle Biosciences position peaked at $2.81M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.